HI Leslie - as you know I do a bit of work in the continence field... wondered why we did not use this medication in human patients so did a bit of googling, looks like it is banned here in human use because of the reasons I have copied below. Sounds like a nasty drug to me and glad you have stopped it, if it is not safe for humans not sure why they use it in our beloved pets. Best of luck sorting out Squirt's issues, if anyone can do it, you can!!
Trish xx

Background
Norephedrine is a stereoisomer of phenylpropanolamine, which is listed under the Medicines Act 198. Norephedrine/phenylpropanolamine was previously used as an
appetite suppressant and a decongestant but the risk of side effects means that it will not be used in human medicine in future. There are no human medicines containing phenylpropanolamine now available in New Zealand.
Phenylpropanolamine is used in veterinary medicine: the product Propalin® is registered under the Agricultural Compound and Veterinary Medicines Act 1997 and is used for canine urinary incontinence.
Norephedrine is also a precursor substance that can be used in the manufacture of amphetamine, a Class B1 controlled drug.
The Committee’s advice regarding norephedrine
2
The Committee agreed that there is a potential risk of norephedrine being imported into New Zealand or diverted from domestic sources in order to be converted into amphetamine.
It was also agreed that in view of the current proposals to reclassify
pseudoephedrine and ephedrine (precursors to methamphetamine) as Class B2 controlled drugs, if norephedrine is classified lower than Class B2 it could provide an incentive for the importation of norephedrine and increased amphetamine manufacture.
The Committee considered that there would only be a limited effect on industry should this substance be classified; however, a Class B2 classification would require consultation with relevant stakeholders such as veterinarians. Consideration would also be required on the continued status of phenylpropanolamine as a registered animal remedy and its classification as a prescription medicine under the Medicines Act.
Finally, the Committee agreed that norephedrine would not be appropriately
scheduled as a Schedule 4, Part 2 precursor substance, as it is considered a ‘primary’ precursor (for amphetamine). The Committee also agreed there is insufficient information currently available to justify the scheduling of norephedrine